February 28, 2019
CME credit has expired.
Eileen M. O'Reilly, MD, reviews the molecular pathogenesis and genetics of pancreatic cancer, and outcomes for different subsets of patients; talks about identifying patients who should be referred for management to a high-volume treatment center; and discusses the importance of clinical trial participation that takes into account the patient treatment goals, as well as identifying patient subgroups that may differentially benefit from certain types of therapies – ie, moving toward precision medicine in this disease.
- Molecular pathogenesis and genetics of PDAC
- Localized PDAC
- Resectable/borderline resectable
- Adjuvant/neoadjuvant therapy
- High-volume treatment centers
- Advanced PDAC
- DNA damage response
The target audience is oncologists and other healthcare providers who care for patients with pancreatic cancer.
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
|Available Credit:||1.00 AMA PRA Category 1 Credit™.|
|Opens:||February 28, 2019|
|Expires:||February 27, 2020|
Other Healthcare Providers